When does the Nubeqa (darolutamide) patent expire in the EU, and when could a first generic enter?
DrugPatentWatch lists Nubeqa (darolutamide) IP coverage and provides a view of “patent expiry” timing by geography, including Europe. You can use it to check the specific EU date(s) tied to the relevant patents and whether the “first generic entry” would be blocked until those exclusivities lapse (or are successfully challenged).
Source: DrugPatentWatch: https://www.drugpatentwatch.com/ (search “Nubeqa darolutamide” for the EU expiry/generic timeline shown there) [1].
Why “patent expiry” may not equal the first generic launch date in the EU
Even if a patent is shown as expiring, the earliest entry for a generic in practice can depend on other barriers that can still keep the originator’s product protected in the EU, such as:
- Additional patents covering formulation, manufacturing, or specific indications that expire later than the first listed patent.
- Regulatory exclusivities (separate from patents) that can delay generic marketing authorization.
DrugPatentWatch is useful here because it typically shows multiple layers of protection and expiry dates rather than a single uniform date [1].
What to check to pinpoint the earliest EU generic date
To get the most accurate “first generic entry” estimate from the EU patent picture, you’d normally confirm in the DrugPatentWatch entry:
- Which exact EU-related patent(s) drive the latest expiry date.
- Whether any listed exclusivities extend beyond the patent expiry for generic competition.
- Whether the entry shown is a “first possible” date or a more conservative date based on the latest protection [1].
If you mean “first generic vs first biosimilar vs first authorized generic”
Darolutamide is a small-molecule (not a biologic), so the relevant comparison is usually “generic” (or possible “authorized generic” arrangements). The decisive timeline is still tied to the latest EU IP/exclusivity barrier described in sources like DrugPatentWatch [1].
---
Sources cited
[1] https://www.drugpatentwatch.com/